title: Adult Pompe disease: clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy.
abstract: OBJECTIVE
  Pompe disease is an autosomal recessive lysosomal disorder caused by α-glucosidase deficiency. A specific treatment for the disease with enzyme replacement therapy is currently available. The aim of the present study is to describe the clinical manifestations and the effect of treatment in the first Greek patients with the adult form of the disease.
  
  
  METHODS
  Five Greek patients with adult onset Pompe disease aged between 40 and 73 years received 20 mg/kg Myozyme intravenously at two weekly intervals over a different period. Clinical and functional parameters were longitudinally registered.
  
  
  RESULTS
  Proximal muscle weakness and respiratory insufficiency were the most common manifestations of the disease, but their severity was different even among patients with similar genotype. The effect of treatment varied with most patients experiencing some improvement in muscle strength and fatigability, while the most severely affected patient did not benefit and stopped therapy.
  
  
  CONCLUSIONS
  No clear genotype-phenotype correlation emerges from our study. The different effect of treatment on our patients seems to be mainly related to their pre-treatment condition and can be reliably assessed only on a long term basis.
authors.affiliation: Department of Neurology, University of Athens, School of Medicine, Eginition Hospital, Athens, Greece. gkpapad@yahoo.gr
authors.forename: G K
authors.initials: GK
authors.lastname: Papadimas
authors.forename: K
authors.initials: K
authors.lastname: Spengos
authors.forename: A
authors.initials: A
authors.lastname: Konstantinopoulou
authors.forename: S
authors.initials: S
authors.lastname: Vassilopoulou
authors.forename: A
authors.initials: A
authors.lastname: Vontzalidis
authors.forename: C
authors.initials: C
authors.lastname: Papadopoulos
authors.forename: H
authors.initials: H
authors.lastname: Michelakakis
authors.forename: P
authors.initials: P
authors.lastname: Manta
mesh_terms: D000328:Adult; D017668:Age of Onset; D000368:Aged; D001706:Biopsy; D004576:Electromyography; D056947:Enzyme Replacement Therapy; D004798:Enzymes / Q000097:blood; D005260:Female; D020233:Gait Disorders, Neurologic / Q000209:etiology / Q000503:physiopathology; D005838:Genotype; D006009:Glycogen Storage Disease Type II / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology*; D006115:Greece; D006801:Humans; D008297:Male; D008875:Middle Aged; D018763:Muscle Fatigue / Q000502:physiology; D053580:Muscle Strength / Q000502:physiology; D018482:Muscle, Skeletal / Q000473:pathology; D010641:Phenotype; D012129:Respiratory Function Tests; D016896:Treatment Outcome; D000520:alpha-Glucosidases / Q000627:therapeutic use*
chemical_list: D004798:Enzymes; C509951:GAA protein, human; D000520:alpha-Glucosidases